Andere Sprachen Eupraxia Pharmaceuticals Inc.

Aktien

A3EGRS

CA29842P1053

EPRX

Verzögert Toronto S.E. Andere Börsenplätze 15:30:00 18.06.2024			% 5 Tage	% 1. Jan.
3,65 ^CAD	0,00 %		-1,08 %	-32,03 %

22.05.	Sektor-Update: Aktien des Gesundheitswesens am Mittwoch vorbörslich schwächer	MT
22.05.	Sektor Update: Gesundheitswesen	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders	06.06.
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	05.06.
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	23.05.
Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	23.05.
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	23.05.
Sector Update: Health Care Stocks Lower Premarket Wednesday	22.05.
Sector Update: Health Care	22.05.
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024	22.05.
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial	22.05.
Eupraxia Pharmaceuticals Reports Positive Data From Eosinophilic Esophagitis Treatment Study -- Shares Rise After Hours	21.05.
Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%	21.05.
Eupraxia Pharmaceuticals Up 70% In US After Hours As Announces New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	21.05.
Eupraxia Pharmaceuticals Inc. Brief: Announcing New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	21.05.
Eupraxia Pharmaceuticals Inc. Announces New Positive Data from Resolve Phase 1B/2A Trial of Ep-104Gi for Treatment of Eosinophilic Esophagitis	21.05.
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	21.05.
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	14.05.
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	08.05.
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board	02.05.
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board	02.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eupraxia Pharmaceuticals Inc.

Aktien

A3EGRS

CA29842P1053

EPRX

Andere Sprachen

Filter